secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001213900-24-043238
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Q1 net loss $3.8M; Phase 2 stenoparib benefit, equity $15M, Nasdaq compliance
--------------------------------------------------------------------------------

- Phase 2 stenoparib trial concluded early due to clear clinical benefits: tumor shrinkage and long-term disease stability in ovarian cancer; preparing follow-on trial with FDA intent.
- Cash balance $14M, stockholders' equity $15M, exceeding Nasdaq $2.5M minimum; seeking formal compliance confirmation.
- Net loss $3.8M for Q1 2024 vs $3.4M Q1 2023; R&D expenses $2.2M (+$0.7M YoY), G&A $2.1M (flat).
- Regained Nasdaq bid price compliance after reverse stock split; capital structure simplified: all variable-priced warrants exercised, Series A Preferred converted.
- Withdrew Form S-1 registration; focus solely on stenoparib, deprioritizing IXEMPRA and dovitinib.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390024043238/0001213900-24-043238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390024043238/ea0206157-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-043238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer